Chengdu Olymvax Stock Soars 8.6%, Hits Intraday High of CNY 31.09

Chengdu Olymvax Biopharmaceuticals, Inc. has experienced significant activity today, with the stock rising by 8.6% and reaching an intraday high of CNY 31.09. This performance stands in contrast to the China Shanghai Composite, which has declined by 1.24% on the same day. Over the past month, Chengdu Olymvax has shown a robust increase of 8.48%, while its year-to-date performance is up by 16.05%. Impressively, the stock has surged by 97.78% over the past year, significantly outperforming the China Shanghai Composite's 16.08% gain. Key financial metrics highlight the company's strong position in the pharmaceuticals and biotechnology sector. The company reported a 25.38% growth in net sales and has achieved a return on capital employed (ROCE) of 6.86%. Additionally, the interest coverage ratio stands at an impressive 1,289.5, indicating strong financial health. With a market capitalization of CNY 7,820 million, Chengdu Olymvax continues to demonstrate solid performance indicators, reinforcing its status in the market.